Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 6/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.31 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23530879 | 0.91 | KLKB1 (0.33) | KLKB1KMT2AMETTL3 | |
| SCHEMBL23530882 | 0.86 | KLKB1 (0.36) | KLKB1KMT2AMETTL3 | |
| SCHEMBL23530631 | 0.83 | KLKB1 (0.35) | KLKB1METTL3 | |
| SCHEMBL23530694 | 0.83 | KCNN3 (0.33) | KLKB1 | |
| SCHEMBL23531012 | 0.80 | KLKB1 (0.34) | KLKB1METTL3P2RX3 | |
| SCHEMBL23530805 | 0.80 | KDM4E (0.49) | METTL3 | |
| SCHEMBL23530747 | 0.80 | ALOX5 (0.31) | KLKB1 | |
| SCHEMBL23530976 | 0.78 | KLKB1 (0.31) | KLKB1 | |
| SCHEMBL23530692 | 0.76 | KLKB1 (0.33) | KLKB1METTL3 | |
| SCHEMBL23530583 | 0.76 | KLKB1 (0.43) | KLKB1METTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230144197-A1 | 4-[[(7-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-5-YL)AMINO]METHYL]PIPERIDIN-3-OL COMPOUNDS AND THEIR THERAPEUTIC USE | Carrick Therapeutics Limited (IE) | 2023-05-11 | — | — | US | disclosed |
| WO-2021122745-A1 | 4-[[(7-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-5-YL)AMINO]METHYL]PIPERIDIN-3-OL COMPOUNDS AND THEIR THERAPEUTIC USE | Carrick Therapeutics Limited (IE) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230144197-A1 | 4-[[(7-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-5-YL)AMINO]METHYL]PIPERIDIN-3-OL COMPOUNDS AND THEIR THERAPEUTIC USE | CDK1, CDK3, CDK2 | KLKB1 2395/4885KMT2A 646/4885METTL3 3227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.